uniQure N.V. heads into September with an interesting divergence: the Street is broadly constructive, short interest is creeping higher, and options traders are showing more defensiveness than at any point in months.
The positioning picture carries a notable internal tension. Short interest has climbed to 17.2% of the free float — already a high reading — and rose a further 3.9% over the past week, adding around 400,000 shares to the short book. That drift higher has been steady rather than aggressive; no single-day spike, just a persistent grind from roughly 10.3 million shares borrowed in mid-August to 10.7 million now. The borrow market itself remains loose. Availability is running at around 930%, meaning there are nearly ten shares available to lend for every one already borrowed — well within the normal range, and a long way from any squeeze pressure. Cost to borrow is also subdued at 0.43%, down roughly 13% on the week. Shorts can add cheaply. The question is what they're seeing that bulls are dismissing. Options are adding a layer to that same cautious tone. The put/call ratio jumped to 0.27 — well above its 20-day average of 0.22 — with a z-score of 2.1, the most elevated defensive posture in the options market in months. Given that the 52-week low PCR is 0.12 and the high is 1.00, the current level is still closer to the call-heavy end of history, but the abrupt directional shift in the past two weeks is the more relevant signal.
The Street, for its part, has been moving decisively in one direction. William Blair reinstated coverage with an Outperform on September 2. After the most recent earnings print in late July, Wells Fargo raised its target from $60 to $75, Wolfe Research upgraded from Peer Perform to Outperform with a $65 target, and even Barclays — which trimmed its target slightly from $65 to $60 — maintained Overweight. Ten analysts carry buy-equivalent ratings; none rate it a sell. The mean price target sits at $60, roughly 25% above the current $47.86. The bull case rests on three pillars: pipeline breadth across Huntington's disease, temporal lobe epilepsy, and hemophilia B; commercial validation through partnerships with Bristol Myers Squibb and CSL Behring; and a forward EPS trajectory ranked in the 89th percentile of the universe for year-on-year improvement. Goldman Sachs is the meaningful outlier — carrying a Neutral with a $46 target, essentially flat to where the stock trades now — and the bear case centres on AMT-130 delays, a U.S. regulatory pathway that offers no accelerated route, and revenue likely pushed to 2030 at the earliest.
Institutional ownership tells a broadly supportive story, though with some churn worth watching. Avoro Capital Advisors holds nearly 10% and added over 750,000 shares in the most recent period. JPMorgan Asset Management reported a substantial 1.97 million share addition. RTW Investments, a specialist healthcare fund, built a 5.7% stake — up from 4.1% in an earlier disclosure — and filed a fresh 13G in August. On the other side, EcoR1 Capital exited completely from a 7.5% position (last disclosed in February), and Vestal Point trimmed from 6.8% to 0.4%. Aberdeen has been steadily reducing, cutting from 8.5% to 4.5% per its July filing. As always with 13D/G filings, these are event-driven disclosures around the 5% threshold; holders dropping below 5% may not file again.
The earnings calendar adds another variable. The stock jumped 15% the day after its most recent print in late July, adding another 5 points over the following week. Before that, the February print drove a 4% one-day gain and a 10% five-day move. Both reactions were positive and material. The next event is scheduled for early November, roughly nine weeks away — far enough out that it isn't the immediate driver, but close enough that options positioning could start reflecting it as the date approaches. The week's 6.2% decline, against a backdrop where close peers DNLI fell 6.7% and LXEO dropped 8.4%, suggests sector-wide pressure rather than a QURE-specific catalyst. RGNX bucked the move with a 4.6% gain, a reminder that individual clinical news can quickly separate names in this space.
The next six weeks come down to whether the pipeline readouts — particularly on AMT-130 in Huntington's disease — generate fresh data that shifts the Goldman Sachs-versus-the-field debate, and whether the slow creep in short interest starts accelerating or reverses.
See the live data behind this article on ORTEX.
Open QURE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
